Sumary of Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19:
- For more information about the use of bamlanivimab with etesevimab to treat COVID-19, click here or contact Lilly’s 24-hour support line at 1-855-LillyC19 (1-855-545-5921).
- Treatment with bamlanivimab and etesevimab together has not been studied in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab and etesevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.
- Serious and unexpected adverse events may occur that have not been previously reported with bamlanivimab and etesevimab together.
- Warnings and PrecautionsHypersensitivity Including Anaphylaxis and Infusion-Related ReactionsSerious hypersensitivity reactions, including anaphylaxis, have been observed with administration of bamlanivimab and etesevimab.
- Infusion-related reactions, occurring during or up to 24 hours after infusion, have been observed with administration of bamlanivimab and etesevimab together.
- Signs and symptoms of infusion-related reactions may include:fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (e.
- atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vasovagal reactions (e.
- Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of bamlanivimab and etesevimab under Emergency Use Authorization.